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Abstract
The primary abnormality in Down syndrome (DS), trisomy 21, is well known; but how this chromosomal gain produces the
complex DS phenotype, including immune system defects, is not well understood. We profiled DNA methylation in total
peripheral blood leukocytes (PBL) and T-lymphocytes from adults with DS and normal controls and found gene-specific
abnormalities of CpG methylation in DS, with many of the differentially methylated genes having known or predicted roles
in lymphocyte development and function. Validation of the microarray data by bisulfite sequencing and methylation-
sensitive Pyrosequencing (MS-Pyroseq) confirmed strong differences in methylation (p,0.0001) for each of 8 genes tested:
TMEM131, TCF7, CD3Z/CD247, SH3BP2, EIF4E, PLD6, SUMO3, and CPT1B, in DS versus control PBL. In addition, we validated
differential methylation of NOD2/CARD15 by bisulfite sequencing in DS versus control T-cells. The differentially methylated
genes were found on various autosomes, with no enrichment on chromosome 21. Differences in methylation were
generally stable in a given individual, remained significant after adjusting for age, and were not due to altered cell counts.
Some but not all of the differentially methylated genes showed different mean mRNA expression in DS versus control PBL;
and the altered expression of 5 of these genes, TMEM131, TCF7, CD3Z, NOD2, and NPDC1, was recapitulated by exposing
normal lymphocytes to the demethylating drug 5-aza-29deoxycytidine (5aza-dC) plus mitogens. We conclude that altered
gene-specific DNA methylation is a recurrent and functionally relevant downstream response to trisomy 21 in human cells.
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Introduction
It is now 5 decades since Down syndrome (DS) was first shown to
result from trisomy 21 [1,2], and some progress has been made
toward understanding the genes that contribute to the complex array
of DS phenotypes – mostly by studying the effects of the trisomy on
transcriptional profiles in humans and mice and by creating
transgenic and trans-chromosomal mouse models [3,4]. We are still
far from understanding the mechanisms that underlie the complex
spectrum of phenotypes in DS. Survival in DS can range from death
in utero to late adulthood; cardiac defects are present in about 40% of
cases, while cognitive disability is invariably present but can range
frommild tosevere. Additionally, thereare multiple blood cell-related
phenotypes including leukemoid reactions and childhood leukemias,
macrocytosiswith orwithoutanemia,amarkedlyincreased incidence
of autoimmune disorders, and increased susceptibility to recurrent
bacterial and viral infections [5–10].
All of these abnormalities must ultimately reflect the down-
stream responses of human cells and tissues to the chromosome 21
aneuploidy. In theory, one mechanism by which cells might
respond to changes in gene dosage is altered DNA methylation.
Gain of methylation at cytosines in CpG dinucleotides in
promoter-associated CpG islands (CGI’s) can enforce dosage
compensation in X-inactivation, and methylation in other types of
CG-rich sequences including intragenic sequences and insulator
elements can affect expression and hence functional gene dosage
at imprinted loci. With these simple ideas in mind we set out to ask
whether gains or losses of genomic DNA methylation might occur
as a downstream consequence of trisomy 21 in blood cells from
adults with DS. Studies profiling mRNA expression in cells and
tissues with trisomy 21 have shown that while many genes on
chromosome 21 are over-expressed, subsets of genes on other
chromosomes also show consistently altered expression in this
background due to gene-gene interactions (for example [11–15]).
So in testing for epigenetic changes downstream of trisomy 21 it is
important to examine the whole genome. Here we show that a
small group of genes, distributed across various chromosomes and
not over-represented on chromosome 21, are consistently altered
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with DS. For a subset of these genes we find altered mRNA
expression in DS versus control blood cells, and we show that this
altered expression can be recapitulated by exposing normal
lymphocytes to the demethylating drug 5aza-dC.
Results
Microarray-based profiling of DNA methylation in DS
versus control PBL
To begin to ask whether PBL from adults with DS might differ
epigenetically from this same tissue in normal adults we first
profiled DS and normal control samples for DNA methylation
genome-wide on high density microarrays, using 2 complementary
platforms: MSNP and Infinium BeadChip assays. The MSNP
method adapts Affymetrix SNP arrays for methylation analysis by
incorporating an initial methylation-sensitive restriction digestion
[16], and queries the methylation status of CpG dinucleotides in
HpaII restriction sites roughly equally spaced along all human
chromosomes in intragenic and intergenic regions (26,800 SNP-
tagged loci reliably informative for CpG methylation in this
experiment; see Methods). In contrast, the Infinium methylation
assay utilizes bisulfite conversion of the genomic DNA and queries
the percent methylation at each of 27,000 CpG dinucleotides
concentrated in promoter regions of 14,000 human genes. We
used MSNP on 250 K StyI SNP arrays to compare 5 DS PBL
samples (4 individuals; one sampled at 2 time points 6 years apart)
to 7 normal control PBL (7 individuals). After calculating the
methylation indices (MIs; see Materials and Methods) and carrying
out non-supervised hierarchical clustering of these data we could
not distinguish the DS from the control PBL samples, suggesting
that trisomy 21 does not cause widespread changes in DNA
methylation in PBL. However, when we analyzed the methylation
values by ANOVA followed by supervised hierarchical clustering,
we found small sets of candidate loci with consistent differences in
methylation in DS versus normal PBL (Figure 1 and Table S1).
We applied Infinium BeadChip methylation assays to a larger
set of PBL DNA samples, comparing 29 individuals with DS to 20
normal controls spanning the same age range. This larger dataset
included all the samples that we had run by MSNP plus additional
cases and controls. Similar to the findings with MSNP, non-
supervised hierarchical clustering of the methylation values
(percent methylation at each CpG queried by the array) showed
no evidence for widespread alterations in DNA methylation in DS
(not shown), but again ANOVA and supervised clustering
produced a list of candidate differentially methylated loci
(Figure 1 and Table S2). The differentially methylated loci in
DS versus normal PBL from both of these microarray screens were
found to be distributed on most of the human autosomes, with no
specific enrichment for genes on chromosome 21 (Tables S1 and
S2).
The reliability of the Illumina Infinium data was shown by
extremely close correlations in technical replicates (examples of x-y
plots and correlation coefficients in Figure S1). To further test
reliability, and to ask whether the sets of differentially methylated
loci clearly distinguish between DS and normal PBL we classified
samples using a logistic ridge regression and validated the
robustness of the classification scheme using leave-one-out cross-
validation. Ridge regression was chosen for the ability of this
approach to control for the colinearity of the independent
variables. Leave-one-out cross-validation demonstrated that the
differentially methylated loci from the Infinium screen classified
DS versus normal PBL with 100% sensitivity and specificity.
Strikingly, we initially observed one apparently mis-classified
sample among the 29 cases of DS (asterisk in Figure 1), but this
individual proved to have mosaic trisomy 21, with less than 50%
trisomic (+21) cells by karyotype. None of the other individuals
analyzed in the microarray experiments showed mosaicism.
This statistical approach was not suitable for the MSNP screen
with the smaller set of samples, but we directly tested and validated
the results for 3 differentially methylated loci from MSNP, as well
as 7 loci from the Infinium screen, using bisulfite sequencing and/
or MS-Pyroseq (see below). As a further technical consideration,
single nucleotide polymorphisms (SNPs) in the regions probed by
the Infinium assays can in principle complicate the results for a
minor subset of loci. However, the absence of common annotated
SNPs detected in the candidate regions from our screen (dbSNP;
http://www.ncbi.nlm.nih.gov/), the representation of several of
the differentially methylated loci by multiple probes on the
BeadChips and, more directly, our successful direct independent
validations by bisulfite sequencing and MS-Pyroseq (see below)
indicated that most if not all of these loci are true positives.
Validations of the microarray data by bisulfite
sequencing
Next we sought to validate the gene-specific differential
methylation in the same DS cases and normal controls using the
independent and definitive methods of combined bisulfite
restriction analysis (COBRA) and bisulfite sequencing. These
validations were successful for 10/10 loci chosen from the lists of
differentially methylated genes that had passed our ANOVA and
fold-change criteria in the microarray data (3 loci from the MSNP
screen and 7 loci from the Infinium screen). Importantly, the
bisulfite sequencing showed that for each gene the differential
methylation affected not only the index CpG sites queried on the
microarrays but also multiple adjacent CpG dinucleotides
(examples in Figure 2, Figures S2, S3 and S4).
Author Summary
Down syndrome (DS; trisomy 21) is caused by the gain of a
single extra chromosome 21. However, the mechanisms by
which this extra chromosome produces the medical
abnormalities seen in DS, including not only mental
retardation but also susceptibility to autoimmune diseases
and recurrent infections, are still not understood. DNA
methylation is a mechanism that might contribute to these
abnormalities. To test this possibility, we profiled DNA
methylation in white blood cells from adults with DS and
normal controls and found recurrent abnormalities of gene
methylation in DS, with several of the differentially
methylated genes having roles in blood cells. Among the
genes with hypo- or hyper-methylation in white blood
cells or purified T-lymphocytes from adults with DS,
compared to these same types of cells from normal adults,
were TMEM131, TCF7, CD3Z, SH3BP2, EIF4E, SUMO3, CPT1B,
NOD2/CARD15, NPDC1, and PLD6. Several of these genes
showed not only different methylation but also different
expression in DS versus control blood cells, which was
recapitulated by exposing normal white blood cells to a
demethylating drug. These findings show that altered DNA
methylation of a specific group of genes is a fundamental
cellular response to the gain of an extra chromosome 21 in
humans. The abnormally methylated genes identified here
may contribute to immune system abnormalities in people
with DS.
DNA Methylation in Down Syndrome
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control PBL by MS-Pyroseq
We next sought to determine the frequency and specificity of
differential methylation in a larger series of individuals. To this end
we used MS-Pyroseq, which measures the percent methylation at
multiple CpGs downstream of the sequencing primer. We applied
this assay to 9 of the candidate loci. For 8 of these loci, TMEM131,
TCF7, SH3BP2, SUMO3, CPT1B, CD3Z, EIF4E and PLD6
(LOC201164) we found strikingly different distributions of
methylation values (percent methylation averaged over multiple
contiguous CpGs) in DS compared to normal PBL (Table 1 and
Figure 3 and Figure S2). The distributions of methylation values
were largely dichotomous, with only minimal overlap between DS
and controls, for TMEM131, PLD6, EIF4E, CPT1B and CD3Z,
while for TCF7, SUMO3,a n dSH3BP2 the distributions were more
overlapping but nonetheless showed a clear shift in the mean values
in DS versus controls. For all of these genes the inter-group
differences in methylation were highly statistically significant
(p,.0001; Table 1). MS-Pyroseq for the ninth gene tested,
FAM62C, revealed a wide range of methylation in both groups
(DS and controls) but the distribution of methylation still differed
significantly, albeit less strongly, between the 2 groups (Table 1). In
summary MS-Pyroseq in the larger case-control series validated the
differential methylation for each of these 9 candidate loci, 3 from
MSNP and 6 from the Infinium assays, thus giving high confidence
in the quality of the primary methylation profiling data.
Age-dependence and stability of the gene-specific
differential methylation
As methylation is known to be age-dependent for certain DNA
sequences in some human tissues including the immune system
[17], for 8 of the independently validated differentially methylated
genes we plotted the percent methylation in DS cases and controls
as a function of age (Figure 3 and Figure S2). For TMEM131, the
average percent methylation clearly declined with age in the
normal controls, but was uniformly low regardless of age in the
adults with DS (Figure 3). Despite the decline with age in the
controls, and our deliberate sampling of PBL from both young and
elderly control individuals, the levels of methylation in this region,
corresponding to a CG-rich internal promoter sequence of the
TMEM131 gene, never reached the very low levels seen in DS.
Similar analyses showed that for all 8 candidate genes tested the
difference in methylation between DS and controls was significant
both before and after adjusting for age (Table 1). As we had
collected PBL samples from several of the study participants with
DS at multiple time points spanning from 6 months up to 7 years,
we were further able to ask whether the methylation abnormalities
were stable over time in these individuals. As shown in Table S3,
the degree of methylation as determined by MS-Pyroseq was
generally stable over time.
Mosaicism for trisomy 21 can be found in a minor subset of
individuals with DS, and this finding has been associated with less
severe phenotypes. The large majority of DS cases in our series
Figure 1. Microarray analysis of DNA methylation in DS versus normal PBL. A, Supervised hierarchical clustering of the MI values from
Affymetrix 250 K StyI MSNP. Applying ANOVA (p,.01) and a fold-change criterion (.1.2 fold change in MI in DS versus normal PBL) produced a set of
70 differentially methylated loci. The MI values for these loci were subjected to hierarchical clustering in dChip. Biological samples are on the x-axis
and SNPs are on the y-axis with strong methylation indicated by the red color and weak or absent methylation by the blue color. B, Supervised
hierarchical clustering of the Illumina Infinium data (fractional methylation) for 108 genes (118 probes) that passed ANOVA at p,.01, with additional
criteria of .1.2 fold change and .0.1 absolute difference in DS versus normal PBL. The AML cases were not included in the statistical analyses but are
shown here to highlight the fact that the perturbations in methylation in DS versus normal PBL are different and smaller in magnitude (less intense
red and blue color) than in normal PBL versus AML. The asterisk indicates the single case of mosaic DS, which shows a pattern of methylation
intermediate between DS and controls. C, Supervised hierarchical clustering of the Illumina Infinium data (percent methylation) for 140 CpGs, located
in 134 different genes that passed ANOVA at p,.01 and the fold-change criterion (.1.3 fold change and ..15 absolute difference) in fractional
methylation in DS T-cells versus normal T-cells. Genes mapping to the X or Y chromosomes were removed from each dataset (see Materials and
Methods).
doi:10.1371/journal.pgen.1001212.g001
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Infinium BeadChips and all three of which were analyzed by MS-
Pyroseq) showed moderate to high mosaicism with cells disomic
for chromosome 21 constituting .15% of the leukocytes in the
peripheral blood. While the rarity of these mosaic cases precluded
a statistical analysis, as shown in Table S4 the cases with the
greatest percentage of normal diploid cells (high level mosaics)
showed methylation values closer to the normal range.
The abnormal DNA methylation in DS PBL is not due to
altered cell counts
Abnormalities of B- and T-lineage lymphocytes, either func-
tional, numerical or both, have been reported in children and
adults with DS [18–25]. We therefore considered whether grossly
altered blood cell differential counts with normal cell type-specific
variation in DNA methylation might trivially account for our
findings of altered methylation in DS. We first performed
automated complete blood counts for 4 of the DS blood samples,
all of which showed strongly reduced methylation of the internal
promoter of TMEM131 and the upstream region of TCF7 and
increased methylation of the upstream portion of the SH3BP2
CGI. We found that the numbers and percentages of polymor-
phonuclear leukocytes (PMNs) and total lymphocytes were all
within the normal range for our clinical laboratory (Table S5). The
percentages of monocytes were slightly increased (range in the 4
DS cases 6.4–11.9 percent; normal range 4–8 percent, Table S5)
but as measurements of DNA methylation linearly average over all
cells in a given sample, this slight increase in a minor cell
population would not be sufficient to account for the altered
methylation in DS PBL. We next fractionated several normal PBL
samples into mononuclear cells (PBMCs) versus PMNs on Ficoll
gradients and performed COBRA and MS-Pyroseq on the
genomic DNAs. This analysis revealed cell type-specific methyl-
ation levels, but we found no evidence for differences in
methylation of TMEM131, SH3BP2, EIF4E,o rTCF7 between
these 2 cell populations with a direction and magnitude that could
account for the altered methylation observed in DS, even if cell
numbers were altered (Figure 2A and Figure S4). Only for one of
Figure 2. Validation of differential DNA methylation in the TMEM131 gene in DS versus normal PBL. A, COBRA showing markedly less
methylation in DS compared to normal PBL (left panel). The right panel shows COBRA results for PBMC, PMN, NK-T and NK cell fractions from normal
blood. None of these lanes show the pattern seen in DS PBL, indicating that the loss of methylation in DS PBL is not due to changes in the
proportions of these normal cell populations. U, unmethylated; M, methylated. IVM, in vitro methylated DNA. B, Bisulfite sequencing showing that the
hypomethylation in the promoter of the short isoform of TMEM131 in DS affects a large number of contiguous CpGs. C, map of the TMEM131 locus,
showing the major alternative transcripts. The differential methylation is in the promoter of the short isoform (grey bar, near the index SNP
rs6760008); bisulfite sequencing of the far upstream CGI showed absence of methylation in both DS and controls (white bar; data in Figure S6).
doi:10.1371/journal.pgen.1001212.g002
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Gene Name
Affy SNP ID or
Illumina CG ID
Mean % methylation;
including multiple
time points
Mean % methylation;
single time points only
Gene Product and
Function
Tissue-Specific
Expression
a
TMEM131
(Chr2)
SNP_A-2136365; Inter-
nal promoter region
(CG-rich but not meet-
ing criteria for CGI
b)
DS, 10.9
(n=207)
Control, 41.1
(n=73)
p,.0001
DS, 10.9
(n=186)
Control, 40.8
(n=67)
p,.0001
Transmembrane protein
(long isoform); structure
of smaller protein isoform(s)
unknown.
Highest expression in
spleen and thymus. Str-
ongly expressed in hema-
topoietic stem cells, my-
eloid precursor cells, NK, T-
and B-lymphocytes. Expre-
ssion in NK cells induced
by IL-2/PHA. Expression
increases between the
multipotent progenitor
and pro-T cell stage.
TCF7
(Chr5)
SNP_A-2179466; conserv-
ed CG-rich region 5 kb
US of promoter CGI
DS, 26.5
(n=207)
Control, 44.0
(n=64)
p,.0001
DS, 26.6
(n=191)
Control, 44.2
(n=59)
p,.0001
Transcription factor
(a.k.a. TCF-1); role in
Wnt signaling pathway;
essential for NK cell
development.
Highest expression in
whole thymus, NK cells
and T cells. Expression in
NK cells is suppressed by
IL-2/PHA. Expression incre-
ases strongly between the
multipotent progenitors
and pro-T cell stage.
SH3BP2
(Chr4)
cg07991621 and
cg08822227; pro-
moter CGI
DS, 34.5
(n=203)
Control, 23.6
(n=67)
p,.0001
DS, 34.9
(n=185)
Control, 23.0
(n=64)
p,.0001
Cytoplasmic protein;
signaling adaptor. Essential
for normal B-cell and NK
cell function.
Highest expression in
blood cells, including B
cells, T cells, NK cells,
monocytes and myeloid
precursor cells. Expression
in NK cells induced by
IL-2/PHA.
FAM62C
(Chr3)
SNP_A-1974529;
0.5 kb US of pro-
moter CGI
DS, 46.0
(n=87)
Control, 40.1
(n=45)
p=.005
DS, 46.1
(n=81)
Control, 39.8
(n=40)
p=.005
C2-domain protein;
synaptotagmin family.
Precise function not known.
Highest expression in lung
and brain; weaker expre-
ssion in hematopoietic
cells.
CD3Z
(CD247)
(Chr1)
cg09554443;
first exon; no CGI
DS, 16
(n=113)
Control, 29
(n=45)
p,.0001
DS, 16.3
(n=90)
Control, 29
(n=45)
p,.0001
T-cell receptor zeta chain
isoform 2 precursor. Crucial
for T-cell signaling.
High expression in whole
blood, NK cells, T cells, B
cells, thymus and bone
marrow.
PLD6
(LOC201164)
(Chr17)
cg05590257;
promoter CGI
DS, 23.1
(n=105)
Control, 10.8
(n=40)
p,.0001
DS, 23.4
(n=88)
Control, 10.9
(n=39)
p,.0001
Phospholipase D6. Precise
function not known.
Widely expressed.
EIF4E (Chr4) cg14972143; 500 bp
US of promoter CGI
DS, 24
(n=110)
Control, 14.7
(n=42)
p,.0001
DS, 23.7
(n=87)
Control, 14.7 (n=42)
p,.0001
Eukaryotic translation initiation
factor 4E. Essential for efficient
translation of cell proliferation-
related genes.
Highest expression in
bone marrow CD34+ he-
matopoietic stem cells and
in neural tissues.
CPT1B
(Chr22)
cg00983520; pro-
moter CGI
DS, 71.1
(n=73)
Control, 46.2
(n=33)
P,.0001
DS, 71.9
(n=58)
Control, 46.2
(n=33)
P,.0001
Carnitine palmitoyltransferase
1B. Metabolic enzyme.
Highest in heart, testis,
CD34+ hematopoietic
cells, T cells and B cells.
SUMO3
(Chr21)
cg21053323; pro-
moter CGI
DS, 53
(n=98)
Control, 40.7
(n=39)
p,.0001
DS, 53.3
(n=75)
Control, 40.3 (n=36)
p,.0001
Small ubiquitin-like modifier
protein 3. Multiple functions
exerted via post-translational
protein modifications.
High expression in bone
marrow CD34+ hemato-
poietic cells, NK cells, B
cells, dendritic cells and
monocytes.
The p-values are for differential methylation from logistic regression adjusting for age. These calculations are shown both for the series including individuals with DS
who provided PBL samples at multiple time points from 6 months to 7 years apart, and for same series of individuals narrowed to include only the first blood draw. As
shown here, all 9 candidate loci tested by MS-Pyroseq showed highly significant differential methylation concordant with the microarray data. These results give strong
confidence in the overall accuracy of the microarray data; complete lists of differentially methylated loci are in Tables S1 and S2.
aExpression summaries are from the GNF Expression Atlas 2 microarray data (http://expression.gnf.org/cgi-bin/index.cgi), Unigene (http://www.ncbi.nlm.nih.gov/
UniGene/ESTProfileViewer.cgi), and microarray data in NCBI/GEO accession GDS751, see [25]. HSC, CD34+ hematopoietic stem cells.
bCGI criteria are: GC content of 50% or greater; length greater than 200 bp; ratio greater than 0.6 of observed number of CG dinucleotides to the expected number on
the basis of the number of Gs and Cs in the segment.
doi:10.1371/journal.pgen.1001212.t001
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difference in methylation in PBMC compared to PMN with a
magnitude and direction that could possibly account for the
observed differential methylation in DS versus normal PBL based
on abnormal lymphocyte numbers. However, we were able to
exclude this trivial explanation for CD3Z by showing that its CpG
methylation is specifically altered in purified T-cells from DS
versus controls (below). Lastly, given that one of the reported
findings in adults with DS is an increase in the minor sub-
population of T-lineage lymphocytes with the immunophenotype
of natural killer (NK) cells, we did a further control assessing the
methylation of TMEM131 in DNA from NK cells immunopurified
from normal individuals. This analysis showed that the critical
region of the TMEM131 gene is in fact slightly hypermethylated in
normal NK cells; a pattern opposite to the hypomethylation seen in
whole blood from DS (Figure 2A). Similar results excluding the
possibility that the observed alterations in methylation might be
trivially due to increased numbers of normal NK cells were
obtained for the TCF7 and SH3BP2 genes (Figure S4).
Gene-specific abnormalities in DNA methylation in T-
lymphocytes from DS
To directly assess CpG methylation within an important
lymphocyte subset, we next prepared genomic DNA from T-cells
immuno-purified from PBL of 12 individuals with DS and 15
control individuals, and measured SUMO3, CD3Z and SH3BP2
promoter methylation, as well as methylation of the TMEM131
internal promoter region, by MS-Pyroseq. This procedure
confirmed that all of these loci are differentially methylated
between DS and normal controls, not only in whole PBL but also
in the T-cell preparations, thus arguing against our findings in DS
PBL being trivially due to altered numbers of (epigenetically
normal) T-cells (Figure S5). To obtain genome wide methylation
data in this cell type, we next profiled promoter methylation in T-
cell DNAs from 4 normal adults and 6 adults with DS for which
sufficient DNA was available, using the Infinium BeadChips.
Similar to our findings using total PBL, ANOVA followed by
supervised clustering of the methylation values revealed a small set
of differentially methylated loci (140 CpGs, located in 134
different genes) in this DS versus normal T-cell comparison
(Figure 1 and Table S6). Among the 108 genes (118 probes)
identified as differentially methylated in our Infinium data from
DS versus normal total PBL, a large subset, 17 genes (19 probes),
were also found to be differentially methylated in this genome-
wide analysis with the T-cell preparations. This observation of
gene-specific differential methylation in purified T-cells from DS
versus control individuals further supports our conclusion that the
epigenetic changes reported here reflect bona fide abnormalities
within specific cell types and cannot be trivially accounted for by
altered percentages of the major types of leukocytes.
Altered expression of TMEM131, TCF7, and NPDC1 in DS
PBL
DNA methylation in cis-acting regulatory sequences can affect
gene transcription, with hypermethylation of CG-rich promoter
regions causing or consolidating transcriptional repression and
Figure 3. Quantitative MS-Pyroseq showing recurrent hypomethylation in the TMEM131 internal promoter region, TCF7 upstream
region, and CD3Z promoter region, and hypermethylation in the EIF4E, SH3BP2, SUMO3, and PLD6 promoter regions, in DS compared
to normal PBL. Genomic DNAs were bisulfite converted and subjected to PCR followed by MS-Pyroseq. The values for percent methylation are
averaged over multiple CpG dinucleotides in each region, as listed in Table S7. Mean values for methylation and the p-values from logistic regression
adjusting for age are in Table 1. DS, total PBL from adults with DS; Control, total PBL from normal adults; CB, total leukocytes from normal umbilical
cord blood; PBMC, normal adult peripheral blood mononuclear cells; PMN, normal adult peripheral blood polymorphonuclear leukocytes.
doi:10.1371/journal.pgen.1001212.g003
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an opposite phenomenon of increased gene expression. Total
RNA was available from some, though not all, of the PBL samples
in this study, and we measured mRNA transcript levels in these
samples by Q-PCR. As shown in Figure 4, isoform-specific Q-
PCR revealed, as predicted, greater amounts of mRNA initiating
from the internal promoter region of TMEM131 in the DS PBL
samples (in which this region is relatively hypomethylated)
compared to normal PBL (in which this region has substantial
methylation). In contrast, expression of the longer TMEM131
mRNA isoform initiating from the upstream CGI-associated
promoter, which was uniformly unmethylated in both DS and
normal PBL, did not differ between these 2 groups (Figure S6). As
a second example, NPDC1 was among the genes that showed
consistent promoter hypomethylation in DS compared to normal
PBL by the Infinium assays (Table S2) and Q-PCR for NPDC1
mRNA revealed that the DS PBL samples showed, on average,
greater expression of this gene than the normal PBL samples
(Figure 4). A third example was TCF7, for which Q-PCR revealed
that DS PBL samples have, on average, significantly less
expression of mRNA from this gene than the normal PBL samples
(Figure 4). This somewhat unexpected finding suggested that the
evolutionarily conserved region 5 kb upstream of the TCF7
promoter, which is hypomethylated in many of the DS PBL
samples (Table 1, Figure 3 and Figure S2), might be acting as a
negative regulatory element with greater repressive function when
hypomethylated. Further insight was obtained by assessing DNA
methylation directly at the upstream border of the promoter-
associated CGI of this gene by MS-Pyroseq, which revealed a
statistically significant tendency toward hypermethylation in DS
compared to normal PBL (Figure S7). Thus individuals with DS
often have substantial hypomethylation of the conserved region
5 kb upstream of the TCF7 transcriptional initiation site, and also
show a significant though weaker trend toward hypermethylation of
the upstream border of the TCF7 CGI, located closer to the
transcription initiation site.
Overall, these data are consistent with regulation of mRNA
expression at these 3 loci by DNA methylation – a conclusion
further supported by functional experiments using a demethylating
drug (below). However, in interpreting the relatively wide range of
expression in the primary PBL samples it is important to take into
account that the TMEM131, TCF7 and NPDC1 genes are all
known to be highly inducible in response to signaling in NK cells
and probably in other lymphocyte classes (microarray data in
NCBI/GEO, accessions GDS751 and ref. [26]), so the net
expression in a given sample is likely determined by the interaction
between acute environmental signals (cytokines and cell-cell
interactions) and the baseline methylation status of the locus.
Consistent with the acute inducibility of these genes and hence the
wide range of expression in primary blood samples from both DS
and normal individuals, the differences in expression that we
observed were highly statistically significant in the overall
comparisons between DS and normal controls (Figure 4), and
hence correlated strongly on average with the extent of
methylation, but we could not detect strong correlations between
the extent of methylation and the expression level among
individuals within each group.
Recapitulation of the abnormal gene expression by
exposing normal human T-cells to the demethylating
drug 5aza-dC
To test more directly for a functional relationship of
methylation with alterations in gene expression we examined
TMEM131, TCF7, NOD2, SUMO3, CPT1B, CD3Z and NPDC1
mRNA expression in a well controlled cell culture system using the
demethylating drug 5aza-dC. We exposed a proliferating T-cell
line (Jurkat) and, more importantly, normal PBMCs isolated from
fresh peripheral blood samples and expanded with a cytokine (IL-
15) that induces proliferation of cytotoxic T-lymphocytes and NK
cells, or with a general T-cell mitogen (phytohemaglutinin; PHA),
to 5aza-dC for 3 days. We then prepared DNA and RNA from
these cells and measured DNA methylation and mRNA expression
of these 7 genes. In the absence of drug we found more robust
expression of TMEM131 when the PBMCs were expanded with
IL-15, while expression of TCF7, NOD2 and NPDC1 was higher
when these cells were expanded with PHA. All 4 genes were
readily detected in the proliferating Jurkat cells without cytokines.
In experiments using the appropriate mitogens (IL-15 for
analyzing TMEM131 and PHA for analyzing TCF7, NOD2 and
NPDC1) we found that TMEM131 short isoform mRNA, NOD2
mRNA and NPDC1 mRNA levels increased, while TCF7 mRNA
levels decreased, as a function of exposure to 5aza-dC, both in the
Jurkat cells and in the primary PBMCs (Figure 5 and Figure 6).
Figure 4. Altered mRNA expression of TMEM131, TCF7, and NPDC1 in DS versus normal PBL. A, Expression of TMEM131 short isoform
mRNA measured by Q-PCR. The difference between DS and normal controls is highly significant (T-test, p,0.0001). B, Expression of TCF7 mRNA
measured by Q-PCR. The difference between DS and normal controls is highly significant (T-test, p=.00012). C, Expression of NPDC1 mRNA measured
by Q-PCR. The difference between DS and normal controls is highly significant (T-test, p,0.0001). The Q-PCR primers are listed in Table S7. The
TMEM131 Q-PCR primers are specific for the short mRNA isoform; the TCF7 Q-PCR primers amplify both major isoforms of TCF7 mRNA. The NPDC1 Q-
PCR primers amplify all major isoforms.
doi:10.1371/journal.pgen.1001212.g004
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Infinium data for NOD2 by bisulfite sequencing, which confirm the
relative loss of methylation in T-cells from DS patients, compared
to T-cells of normal adults in the (non-CGI) promoter region of
this gene. These data are consistent with a functional role for DNA
methylation in modulating the expression of these genes in
lymphocytes (and possibly in monocytes as well) and for the 3
genes from the PBL screen the directions of their changes in
expression upon demethylation (increased for TMEM131 and
NPDC1 and decreased for TCF7) match the predictions based on
the differences of their average expression levels in DS versus
normal PBL (Figure 4). For another two genes, NOD2 and CD3Z,
our analysis of mRNA expression is still in progress but the
aggregate results so far are consistent with these two genes being
functionally regulated by promoter methylation. The DNA
methylation data (both genes hypomethylated in DS T-cells
compared to normal T-cells) and 5aza-dC response (significantly
increased expression of both genes on exposure of normal PHA-
stimulated PBMC to the demethylating drug) are consistent with a
functional role for CpG methylation in down-modulating
expression of these genes in normal T-cells (Figure 6 and data
not shown). Furthermore, in a small number of purified T-cell
samples analyzed so far (7 DS T-cell and 8 normal T-cell
preparations) both of these genes are over-expressed on average in
the DS T-cells compared to normal T-cells (2-fold for NOD2 and
2.5-fold for CD3Z). However, these Q-PCR data have shown high
inter-sample variability and have not yet reached statistical
significance by T-tests.
Figure 5. Effects of the demethylating drug 5aza-dC on expression of TMEM131 short isoform, TCF7, and NPDC1 mRNAs in Jurkat
cells and normal human T-cells expanded with mitogens. A, Increased expression of TMEM131 short isoform mRNA in Jurkat cells and PBMC
exposed to 5aza-dC at the indicated concentrations for 3 days. The short-term cultures of PBMC were grown in the presence of IL-15 to induce
proliferation of cytotoxic T-cells and NK cells. B, Decreased expression of TCF7 mRNA in Jurkat cells and PBMC exposed to 5aza-dC at the indicated
concentrations for 3 days. The short term cultures of PBMC were grown in the presence of PHA to induce a polyclonal proliferation of T-cells. PHA
rather than IL-15 stimulation was utilized for assessing TCF7 expression and response to 5aza-dC because the baseline expression of TCF7 mRNA is
high after PHA stimulation but very low after stimulation with IL-15. C, Increased expression of NPDC1 mRNA in Jurkat cells and PBMC exposed to
5aza-dC at the indicated concentrations for 3 days. The short term cultures of PBMC were grown in the presence of PHA to induce a polyclonal
proliferation of T-cells. In each experiment a 25 – 40 percent reduction in DNA methylation of the index regions of interest after exposure to the
highest dose of 5aza-dC was confirmed by MS-Pyroseq or bisulfite sequencing (data not shown). Cell viability was preserved in each experiment, but
net cell proliferation was reduced by approximately 50% at the highest doses of 5aza-dC.
doi:10.1371/journal.pgen.1001212.g005
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NOD2, CD3Z and NPDC1, the two remaining differentially
methylated genes that we tested, SUMO3 and CPT1B, have shown
negative data or paradoxical correlations between CpG methyl-
ation, mRNA expression and response to 5aza-dC. For the
SUMO3 gene, located on chromosome 21, we found by Q-PCR
that the mean expression level in DS PBL is about 1.5-fold greater
than in normal PBL, thus being consistent with a simple physical
gene dosage effect, with no obvious compensatory effect of the
promoter hypermethylation (data not shown). For the CPT1B gene
Q-PCR revealed a paradoxical correlation between promoter
hypermethylation and significant over-expression of CPT1B
mRNA in DS PBL. This paradoxical relationship was not clarified
by examining the response of CPT1B transcription to 5aza-dC, as
the demethylating drug caused a slight increase, not a decrease, in
its mRNA levels both in Jurkat cells and in normal PBMC (data
not shown).
Discussion
The primary cause of DS, namely trisomy 21, has been known
since 1959, but the pathogenesis of the diverse phenotypic
features of this syndrome, not only in brain and cardiac
development but also in a range of blood cell-related phenotypes
including macrocytic anemia, autoimmunity, and recurrent
infections, remains incompletely understood. Profiling of mRNA
in cells and tissues with +21 has revealed widespread changes in
gene expression, mostly small in magnitude, both for genes on
chromosome 21 and for large groups of genes on other
chromosomes. However sorting out the importance of any given
gene has been difficult. Mice with partial trisomies, transgenic
mice, and recently mice engineered to carry human chromosome
21, are useful experimental tools for assigning or excluding roles
of specific genes and regions on chromosome 21 in conferring the
diverse features of DS [27]. But additional experimental
approaches are needed to understand the complex genomic,
cellular and tissue response to this simple chromosomal
aneuploidy.
Previously Chango et al. used a combination of methylation-
sensitive arbitrarily primed polymerase chain reaction (MS-AP-
PCR) and quantitation of DNA fragments to find 6 fragments that
were hypermethylated in PBL from 8 individuals with DS,
compared to 8 normal controls [28]. The authors suggested that
the observed differences might provide a mechanism to silence
constitutively over expressed genes in DS, but the methods did not
allow the DNA sequence of these fragments to be determined.
Here we have taken a genome-wide screening approach using 2
independent platforms that are entirely distinct in how they query
methylation and are complementary and largely non-overlapping
in their coverage of CpG sites. MSNP uses methylation-sensitive
restriction digestion as the initial step to query the methylation
status of CpG dinucleotides in HpaII restriction sites in intragenic
and intergenic regions, most of which are not promoter-associated;
in contrast the Infinium methylation assay utilizes bisulfite
conversion of the genomic DNA as the initial step and queries
the percent methylation of CpG’s in promoter regions, including
many CpG islands as well as a large number of non-island
promoter sequences. These genome-wide microarray-based
screens, with validations by independent methods in a larger
series of DS cases and controls, show that there are highly
recurrent gene-specific epigenetic changes in this common
chromosomal disorder.
Our results are from analyzing blood cells, so it is important to
consider what is known about the effects of trisomy 21 in this cell
lineage. There are indications from studying mosaicism over time
that trisomy 21 is weakly but continually selected against in
hematopoietic cells [29–31]. Related findings in well controlled
mouse models include strongly reduced growth capacity of bone
marrow stem cells in the partial trisomy Ts65Dn model of DS
[32], defects in hematopoietic progenitor cells and macrocytosis in
a related partial trisomy mouse model, Ts1Cje [33], as well as
hematopoietic abnormalities in the more recently created Tc1
trans-chromosomal model [34]. Combining these observations
with our current data, one possibility is that there may be
biological selection over time for specific patterns of altered DNA
methylation in hematopoietic stem/progenitor cells that affect net
cellular proliferation in this aneuploid genetic background.
Ongoing biological selection acting on stochastic variations in
DNA methylation could result in altered DNA methylation, as
observed here, and changes in biological properties, such as the
Figure 6. Differential DNA methylation in the CARD15/NOD2 gene in DS versus normal T-cells and induction of NOD2 mRNA by 5aza-
dC. A, Fractional methylation values from the Infinium assays showing differential methylation at cg26954174 in the NOD2 promoter region in DS
versus control T-cells. B, Bisulfite sequencing showing relative hypomethylation in the (non-CGI) promoter region of NOD2 in DS T-cells. The map of
the NOD2 promoter region shows the location of the Infinium probe (grey bar above the line, cg26954174); the region subjected to bisulfite
sequencing is shown by the grey bar below the line. C, Increased expression of NOD2 mRNA in PBMCs exposed to 5aza-dC at the indicated
concentrations for 3 days. The short term cultures of PBMCs were grown in the presence of PHA to induce a polyclonal proliferation of T-cells.
doi:10.1371/journal.pgen.1001212.g006
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alternative explanations for our findings, major changes in the
DNA methylation machinery are less likely, given that the
microarray data show only gene-specific and not widespread
alterations in DNA methylation.
Immunological abnormalities are prominent in DS, and many
of the differentially methylated genes in Table 1, Tables S1 and S2
have known or predicted roles in the immune system. Among the
genes that we have focused on for downstream analyses in this
study several (TCF7, SH3BP2, CD3Z and NOD2) are already
known to be essential for normal lymphocyte development and
function, while another group (TMEM131, PLD6, NPDC1and
EIF4E) are interesting candidates for such a role. TMEM131
methylation in the internal promoter region is strikingly and
consistently different in DS versus normal PBL, and this gene,
encoding a transmembrane protein, has been shown to be
cytokine-inducible in NK cells, together with another gene that
we have studied here, NPDC1 (microarray data in NCBI/GEO,
accession GDS751; ref. [26]). These genes are therefore intriguing
biological candidates for contributing to the pathogenesis of NK
cell defects in DS. Little information is available on the function of
TMEM131 but this gene was reported to be sharply up-regulated
between the multipotent progenitor and pro-T cell stages of
differentiation, along with only a few other genes, strikingly
including another gene which we have shown here to be
abnormally methylated in DS, namely the transcription factor
gene TCF7 [35], which is known to be essential for normal NK cell
function [36–39]. While these genes are evidently co-regulated in
development, they can respond oppositely to acute exposures to
cytokines: expression of TMEM131 and NPDC1 in NK cells is up-
regulated by IL-2/PHA while TCF7 expression is down-regulated
(microarray data in NCBI/GEO accession GDS751 [26]).
This fact is interesting in view of the inverse abnormalities in
expression of TMEM131 and NPDC1 (increased) compared
to TCF7 (decreased) in DS PBL, which is paralleled by the
inverse responses of these genes to DNA demethylation in our
experiments using 5aza-dC.
Considering the possible functions of some of the other
differentially methylated genes, NOD2 encodes a pathogen
recognition receptor that is often studied in monocytes and
macrophages but it is also expressed by CD34+ hematopoietic
stem/progenitor cells and FOXP3-positive T regulatory cells [40].
SH3BP2 codes for a pleckstrin homology domain- and Src
homology 2 (SH2) domain-containing adaptor protein that is
preferentially expressed in hematopoietic tissues including macro-
phages, NK, T-, and B-cells. It is involved in leukocyte signaling
downstream Src/Syk-kinases and plays a crucial role in signaling
during cell differentiation [41]. PLD6, encoding a member of the
phospholipase-D family, has not yet been studied for its role in
lymphocyte physiology but other phospholipase-D family mem-
bers are known to be crucial for signaling downstream of the T-cell
receptor [42]. EIF4E, encoding a translational initiation factor that
is rate-limiting for expression of numerous proliferation-related
cellular proteins, is up-regulated during T-cell activation and
promotes lymphocyte chemotaxis [43,44]. SUMO3 is one of a
family of small sumo proteins that modify the activities of other
cellular proteins by post-translational sumoylation – a process that
is known to affect lymphocyte physiology including regulation of
immunoglobulin production by B-cells [45] and mitogenesis and
cytokine production in T-cells [46,47]. The biological role of the
protein encoded by the NPDC1 gene is not yet known, and
knockout mice lacking this gene did not show an obvious
developmental phenotype [48]. Based on our findings of altered
methylation and expression of this gene in DS PBL, and the
observation of its induction during NK cell activation noted above,
it would be interesting to study immune system function in the
Npdc1-deficient mice. Tables S1 and S2 contain additional
examples of differentially methylated genes encoding cytokines,
receptors and transcription factors that also warrant examination
for roles in the normal immune system and in the immunological
abnormalities associated with DS.
In summary, our findings show that recurrent gene-specific
alterations in CpG methylation are a stereotypical cellular
response to trisomy 21, with functional consequences in gene
regulation. Interesting gene candidates for the immune dysfunc-
tion in DS are already emerging from these data, and as insights
from studying DS as a model system have often shed light on
physiological mechanisms in the general population it will also be
important to dissect the roles in the normal immune system of the
genes from our screen. Additional screens, including analysis of
other tissues such as heart and brain, will be useful for pinpointing
loci that are recurrently altered by gains or losses of DNA
methylation in other cell types that contribute to key aspects of DS
such as cardiac defects and cognitive disability. A more general
corollary of our findings, beyond trisomy 21, is that there may be
recurrent and predictable epigenetic consequences of other
chromosomal copy number aberrations - for example in several
types of human cancers, such as leukemias, Wilms tumors, and
sarcomas, that frequently have simple aneuploid karyotypes.
Materials and Methods
Study subjects and diagnosis
This study was approved by Institutional Review Boards of the
New York State Institute for Basic Research and Columbia
University Medical Center. Participants with DS were ascertained
through the New York State developmental disability service
system as well as agencies in New Jersey, Connecticut and
Northern Pennsylvania and have been assessed comprehensively
including full medical chart reviews. The participants were
recruited through responsible state and private service agencies,
who contacted the participant’s families or correspondents for
permission for us to recruit. Informed consent was provided by
either a parent or correspondent, and assent was obtained from
the participant. The distribution of age, level of intellectual
disability and residential placement did not differ between those
participating and those who refused. Age-matched control
participants were laboratory volunteers and participants in the
Washington Heights-Inwood Community Aging Project who gave
informed consent for genetic studies. Confirmation of trisomy 21
by G-banded karyotypes was available for 98% of the study
participants with DS, with 100% concordance between cytoge-
netics and the clinical diagnosis of DS. Of those karyotyped, the
large majority had complete trisomy 21. However, 7 cases
exhibited low level mosaicism with most of the cells having
trisomy 21 and less than 15% of the cells showing a diploid
chromosome complement, 3 cases showed higher level mosaicism
with greater than 15 percent of cells having 46 chromosomes
(disomic for chromosome 21) and six cases presented with
Robertsonian translocations, which in each case produced
complete trisomy for the euchromatic region of chromosome 21
in all cells.
MSNP and Infinium assays for profiling DNA methylation
MSNP on Affymetrix 250 K StyI arrays was carried out
essentially as previously described [16,49,50]. Each biological
sample (total peripheral blood leukocyte DNA) was analyzed by
hybridizing the arrays with genomic representations (probes) made
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digestions of the genomic DNA as the first step in the procedure:
StyI( S), StyI+HpaII (SH), StyI+MspI( SM). All other steps subsequent
to the genomic pre-digestions were according to the Affymetrix
protocol. The S, and SH representations were prepared and
hybridized in duplicate for each biological sample; the SM
representations were single for each sample. Infinium Human
Methylation27 BeadChip (Illumina) assays, based on bisulfite
conversion of genomic DNA followed by primer extension on the
BeadChips to query the methylation status of defined CpG
dinucleotides, were performed according to the protocol from the
manufacturer.
Microarray data analysis
The MSNP data (.cel files) were processed in dChip ([51];
http://biosun1.harvard.edu/complab/dchip/) by normalization,
model-based expression, and chromosome analysis. We assigned a
numerical ploidy of 2 to the S arrays from the normal PBL
samples, leaving the ploidy field blank for all other arrays. This
strategy allowed us to visualize, using the chromosome view in
dChip, the methylation status of HpaII sites flanking a given SNP-
tagged locus as the extent of reduction in signal intensity in the SH
representations, compared to the S representations. As MspI is the
methylation-insensitive isoschizomer of HpaII, the signal intensities
observed in the SM representations allowed us to determine the
reliability of the Class 2 SNPs (those with adjacent HpaII sites thus
informative for methylation status [16,49,50]), with reliable
Affymetrix probe sets indicated by strong reduction in signal in
SM compared to S. For the 26,800 Class 2 loci with SMav/Sav,0.5
we calculated the methylation index (MI) as the fractional
preservation of intensity in SH compared to S. Similar lists of
candidate differentially methylated genes were obtained when we
first subtracted SMav as background and then calculated the
methylation index.
The Infinium BeadChip data were processed using Genome
Studio software, which calculates the percent methylation at each
CpG queried by the arrays. The numerical values for methylation
index (MSNP) and percent methylation (Infinium) were imported
to dChip as external data and analyzed by ANOVA and
supervised hierarchical clustering after removing all probes for
genes on the X or Y chromosome, and applying fold-change and
absolute difference criteria (Results and Figure 1 legend). To
statistically validate the Infinium data we classified DS versus
normal PBL using the % methylation of the differentially
methylated loci in Table S2 using a logistic ridge regression.
The ridge parameter was set to 10
28. Leave-one-out cross-
validation was used to demonstrate that the classifier was not over
trained to our particular test samples. The ridge regression,
sensitivity, and specificity calculations were performed using
Weka 3.4.
COBRA, bisulfite sequencing, and MS-Pyroseq
Genomic DNA, 0.6 to 1 microgram, was bisulfite-converted
using the EpiTect Bisulfite Kit (QIAGEN) according to the
instructions of the manufacturer. Sequences including or adjacent
to the index SNPs or Infinium CpG dinucleotides were amplified
by PCR, using primers designed in MethPrimer [52]. PCR
conditions, primer sequences, and corresponding unconverted
genomic sequences are in Table S7. For COBRA we identified
restriction sites in the converted sequences that differed according
to methylation status of specific CpG dinucleotides and we
digested the bisulfite PCR products with these enzymes followed
by electrophoresis on 1.5% agarose gels. For bisulfite sequencing
the PCR products were cloned using the TopoTA Cloning System
(Invitrogen) and .12 plasmids sequenced for each gene in a given
individual. MS-Pyroseq was performed by bisulfite converting
genomic DNA samples, followed by PCR with gene-specific
primers (designed in MethPrimer) and Pyrosequencing of the
resulting PCR products at EpigenDx (Worcester, MA) using a
Qiagen PSQ instrument. The methylation indices from MS-
Pyroseq were calculated as the average percent methylation of $8
successive CpG dinucleotides between the primers (Table S7).
Quantitative reverse transcription PCR (Q-PCR)
Q-PCR was performed using a 7300 Fast Real-Time PCR
System (Applied Biosystems). Reactions were performed in
triplicate in 96-well optical reaction plates. Each reaction
contained cDNA reverse transcribed from 5 ng total RNA, 1X
Power SYBR Green PCR master mix (Applied Biosystems) and
0.2 mM of each specific primer pair, which were designed using
online D-Lux (Invitrogen) or Primer Express 3.0 software (Applied
Biosystems). The thermal cycling conditions were primer anneal-
ing at 50uC for 2 min and an initial denaturation for 10 min at
95uC, followed by 40 cycles of 15 s at 95uC for denaturation and
1 min at 60uC for annealing and extension. The relative
expression level of a target gene in a particular sample was
calculated by the delta-CT method as described [53].
Purification of NK cells and T-cells
NK cells were purified from human blood to .90% purity
using immunomagnetic beads as previously described [54]. T-cells
were isolated from blood of adults with DS and normal adult
controls to .80% purity using a RosetteSep Kit (Sigma) according
to the manufacturer’s instructions.
Supporting Information
Figure S1 Reliability of the Illumina Infinium data in technical
replicates. In each graph the x- and y-axes indicate fractional
methylation reported by the Infinium assays. A, technical
replicates using PBL DNA from an adult with DS. B, technical
replicates using DNA from a normal control. C, comparison of DS
versus normal PBL. Correlation coefficients are indicated. For
visual clarity, the methylation values for the loci listed in Table S2
are shown here. Similar correlation coefficients in technical
replicates was found using data from all loci on the BeadArrays
(not shown).
Found at: doi:10.1371/journal.pgen.1001212.s001 (0.07 MB
PDF)
Figure S2 Bisulfite sequencing and MS-Pyroseq validating gain
of methylation in the CPT1B promoter region in DS PBL. A,
Bisulfite sequencing showing widespread loss of CpG methylation
in broad regions spanning both ends of the large CGI. B, Map of
the complex CPT1B promoter region, which contains several
predicted alternative first exons. The CGI is represented by the
white bar and the regions subjected to bisulfite sequencing are the
grey bars. C, Result of MS-Pyroseq, showing percent methylation
of a cluster of CpG dinucleotides (see primers Table S7) that are
relatively hypermethylated in DS PBL.
Found at: doi:10.1371/journal.pgen.1001212.s002 (0.28 MB PDF)
Figure S3 Bisulfite sequencing validating gain of methylation in
the PLD6 first exon/CGI region in DS PBL. Bisulfite sequencing
shows a strong and widespread gain of methylation in the CGI of
PLD6 in DS, affecting at least 22 contiguous CpGs. The CGI is
represented by the white bar and the region subjected to bisulfite
sequencing is the grey bar.
Found at: doi:10.1371/journal.pgen.1001212.s003 (0.10 MB PDF)
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methylation in the TCF7 upstream region and gain of methylation
in the CpG Island of SH3BP2 in DS compared to normal PBL. A,
COBRA for the TCF7 upstream region showing less methylation
in DS compared to normal PBL. The fractionated normal samples
analyzed (PBMC, PMN, NKT, NK), and the complete blood
counts (Table S5), indicate that the loss of methylation is not due
to simple numerical changes in the percentages of mononuclear
cells, PMNs, or NK cells (see main text for discussion). U,
unmethylated; M, methylated; P, partially methylated. IVM, in
vitro methylated DNA. B, COBRA for the SH3BP2 CGI region
showing increased methylation in DS compared to normal PBL,
albeit with variability among the cases (compare with large scale
MS-Pyroseq in Figure 3 of the main text). Normal fractionated
mononuclear cells, PMNs and NK cells do not show the abnormal
pattern of methylation seen in DS PBL. C, Bisulfite sequencing
showing that the loss of methylation in the upstream region of
TCF7 in DS affects at least 8 contiguous CpGs. This CG-rich
region is well conserved across vertebrate species, comparable to
exon conservation (Multiz Alignment and Conservation track at
http://genome.ucsc.edu). D, Bisulfite sequencing showing that the
gain of methylation in the CGI region of SH3BP2 in DS affects at
least 10 contiguous CpGs. E, F, maps of the TCF7 upstream
region and CGI and the SH3BP2 CGI region, respectively,
showing the areas analyzed by bisulfite sequencing/COBRA (grey
boxes).
Found at: doi:10.1371/journal.pgen.1001212.s004 (0.19 MB PDF)
Figure S5 MS-Pyroseq confirming altered CpG methylation in
T-cells from DS versus normal controls. The maps show the
regions subjected to MS-Pyroseq (long grey bars) and the locations
of the index SNP for TMEM131 and the most informative
Infinium probes for SUMO3, SH3BP2 and CD3Z (small grey
squares).
Found at: doi:10.1371/journal.pgen.1001212.s005 (0.06 MB PDF)
Figure S6 Isoform-specificity of the epigenetic lesion affecting
TMEM131: lack of differential methylation in the upstream
promoter-associated CGI and lack of differential expression of the
long isoform of TMEM131 mRNA. A, Expression of the long
isoform mRNA measured by Q-PCR shows no difference between
DS and normal PBL. B, bisulfite sequencing of the CGI
corresponding to the promoter region of the long mRNA isoform;
very little methylation is seen in both DS and normal PBL. C, Map
of the TMEM131 genomic locus showing the initiation sites for the
long and short mRNA isoforms. Differential CpG methylation is
present in the immediate upstream region of the short isoform,
which is differentially expressed at the mRNA level (see Figure 3
and Figure 4 in main text).
Found at: doi:10.1371/journal.pgen.1001212.s006 (0.19 MB PDF)
Figure S7 Increased methylation of the TCF7 CGI in DS
compared to normal PBL. The percent methylation was
determined by MS-Pyroseq using primers described in Table S7.
The CGI is indicated by the open rectangle and the region
examined by MS-Pyroseq is shown by the grey rectangle under the
map.
Found at: doi:10.1371/journal.pgen.1001212.s007 (0.06 MB PDF)
Table S1 Differentially methylated loci from the MSNP screen.
Loci with increased methylation in DS are in red and loci with
decreased methylation in DS are in blue (ANOVA p,.01; $1.2
fold difference in methylation index; only unique cases included in
the ANOVA.). The methylation indices were calculated from the
preservation of intensity in the +HpaII genomic representations
(see Materials and Methods).
Found at: doi:10.1371/journal.pgen.1001212.s008 (0.07 MB PDF)
Table S2 Differentially methylated loci from the Illumina
Infinium screen using DNA from PBL. Loci with increased
methylation in DS are in red and loci with decreased methylation
in DS are in blue (ANOVA p,.01; .1.2 fold difference in
methylation index and .0.1 absolute difference in methylation
index; only unique cases included in the ANOVA.) Methylation
indices are the fraction of signal intensity from methylated CpG, as
determined in the Infinium assays, which compare C to T signals
after bisulfite conversion. Coefficients of the logistic regression fit,
which represent size of the contribution of each predictor to
classification status, and their corresponding odds ratios, are
shown in the last 2 columns.
Found at: doi:10.1371/journal.pgen.1001212.s009 (0.06 MB PDF)
Table S3 Stability of DNA methylation over time in adults with
DS.
Found at: doi:10.1371/journal.pgen.1001212.s010 (0.05 MB PDF)
Table S4 Methylation values in cases of DS with mosaicism.
Found at: doi:10.1371/journal.pgen.1001212.s011 (0.06 MB PDF)
Table S5 Complete blood counts in 4 adults with DS. The
normal ranges for Columbia University Medical Center are
indicated.
Found at: doi:10.1371/journal.pgen.1001212.s012 (0.06 MB PDF)
Table S6 Differentially methylated loci from the Illumina
Infinium screen using DNA from purified T-cells. Loci with
increased methylation in DS are in red and loci with decreased
methylation in DS are in blue. Statistical criteria were ANOVA
p,.01; .1.3 fold difference in methylation index and .0.15
absolute difference in methylation index between DS T-cells and
normal T-cells. One further example, the CD3Z gene, was also
differentially methylated both in total PBL and in T-cells, as
indicated by the MS-Pyroseq data (Figure S5), but as the
methylation values were all in a very low range (2 - 14%
methylation) the MS-Pyroseq was more senstive than the Infinium
assay for detecting the difference. One gene, ALX4, which is
queried by the Infinium BeadChip at two different CpG
dinucleotides separated by 5.5 kb, showed opposite changes in
fractional methylation at these two positions.
Found at: doi:10.1371/journal.pgen.1001212.s013 (0.07 MB PDF)
Table S7 PCR primers used in this study.
Found at: doi:10.1371/journal.pgen.1001212.s014 (0.05 MB PDF)
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